Nucleotide Synthesis Technology
DNA & RNA Oligos with high modification + length capacity
Jump to Custom Oligo Tools
Quality Control Criteria
P NMR
UV Characterization
Thin Layer Chromatography
Coupling Test
HPLC
Solubility Test
Nucleotide Synthesis Technology

Harnessing building blocks to develop natures tools. kbDNA’s platform is powered by diverse technical experience in nucleic acid chemistry. This has allowed the integration of proprietary reagents and over 40 years of efficient click-chemistry synthesis to operate under one roof and produce novel ssDNA and RNA.
Our focus is to continue optimizing automated synthesis. This is achieved by chemical intervention at specific solid-phase production points. Thereby reinforcing each step with specialty support to perform target reaction. As a result, kbDNA enables researchers with short (oligo) and long nucleotide sequences to meet their experimental design.
Upgrading Automation in Solid-Phase Synthesis
Upgrading Automation in Solid-Phase Synthesis
01
Detritylation
Step 1 requires starting with a support monomer - traditionally with Controlled Pore Glass (CPG) attached.
02
Coupling
Step 2 involves the coupling of the next monomer with the previous monomer or first support
03
Oxidation
Step 3 follows with eliminating the presence of failure sequences by attaching blocking groups to unreacted sites- improving synthesis fidelity
04
Capping
Stabilizing the phosphate backbone allows for the introduction of the next monomer through continuous repeat of the cycle until the desired sequence is achieved.
05
Completion
Cleavage of all protecting groups off the final product. Cleavage of the final product yields biologically active molecule.
The kbDNA Advantage
Speed
Custimization
Validation
Expertise
Control Your Parameters
Lengths
With our platform, you’ll save time when you need it most. It’s the fastest way to meet your customers’ needs
Modifications
Streamline Catapult your growth by streamlining services and features.
Purity
Our support team is available every day to make sure that things runs smoothly. We’re here to help.
Scale-Up
You’ll enjoy company growth faster than you expected possible, by streamlining services and features.
Applications
PCR | qPCR
Gene Editing | CRISPR
Antisense | siRNA
miRNA | circRNA
LNP's | Therapy
How to Order from kbDNA
THREE STREAMLINED OPTIONS
SeqScreen Calculator
Run your sequence through our properties calculator, and submit the results to us directly.
Custom Synthesis Tool
Start with a base sequence and customize it with our visual tool. Insert bases or modifications. Modify or delete existing bases.
Import Existing Sequence
Already have a sequence, ready to go? Just submit it directly!
Our Simple, Effective System
We'll reply to your submission within 24 hours, with:
Free proofread results by our expert chem-team.
Oligos' performance enhancement recommendations based on your requirements.
Quotes for your original submission, and our recommended alternative.
Manufacturing is in the Genes
Experience and credibility play significant roles in bio scientific research. ChemGenes reagents have been tried and true for decades, contributing non-stop innovations to improve coupling efficiency and the structural capabilities of automated synthesis. Their proven quality and expertise make them not only the most qualified, but also the best partner to compliment kbDNA’s synthesis platform..
Patents & Trademarks
- 2’-O-Methyl, Ethyl phosphoramidite, patent #: US 6,015,886.
- 2’-O-Methyl patent, patent #: US 5,525,719.
- 3’-O-Methyl patent #: US 5,525,719.
- 2’-O-Propargyl modified, patent #: US 5,744,595.
- 3’-O-Propargyl modified Amidites & Solid Supports, patent #: US 5,744,595.
- 2’-Ara-O-methyl amidites, Patent #: US 20120149888.
- Reverse RNA synthesis, patent App #: WO 2011103468.
- Dithiolane based thiol modifier, patent Provisional application #: PCT61/79585.
- Oligonucleotide Labeling-Cycloaddition Reaction, Patent #: US 20120058476.
- Modifications of antimetabolite gemcitabine for incorporation in CpG oligonucleotides, Patent #: US 20110040082
- N6-Trimethyl-L-Lysine & derivative, their therapeutic uses, Patant #: US 20110166230; US 20110166231; US 20110166379; US 20110166380
